|December 2004 · Vol. 16, No. 12
UPDATE on URINARY INCONTINENCE
New Developments That are Changing Patient Care
Promising therapies: TOT, duloxetine, botulinum AAnne
University of Pittsburgh School of Medicine
Department of Obstetrics, Gynecology, and Reproductive Sciences
Ob/Gyns are being called on more than ever to initiate treatment for urinary incontinence, and new treatment options are enabling us to play a more active role than ever before in treating one of the most common and distressing of chronic diseases in women. Urinary incontinence affects women after menopause, primarily. Prevalence increases (though not in a linear fashion)—from 20% to 30% in reproductive-aged women, to 30% to 40% in postmenopausal women. Approximately 16 million Americans are affected, and the number of women affected is more than double that of men.